Astex Pharmaceuticals

Astex Pharmaceuticals applies its proprietary Pyramid Discovery Platform to the identification and development of drug candidates in oncology and central nervous system (CNS) disorders. Operating at the intersection of cutting-edge technology and translational science, the company has assembled research and development teams focused on generating innovative solutions to the complex challenges that characterise both cancer biology and CNS disease.

The company has built a broad product portfolio spanning preclinical and clinical stages. Collaboration and licensing agreements with major pharmaceutical companies underpin part of that portfolio, and three partnered products have reached regulatory approval and are now available on the market. This track record of advancing candidates from discovery through to approved medicines reflects the depth of the company's drug discovery capabilities.

Oncology and CNS Research Focus

Astex's pipeline addresses two of the most challenging and resource-intensive areas of modern medicine. The oncology and CNS drug discovery programmes draw on proprietary technology to identify novel targets and chemical matter, with candidates progressing through preclinical characterisation into clinical evaluation. The organisation also supports early-career scientists through a postdoctoral research programme, reinforcing its commitment to sustaining innovation over the long term.

Headquartered in the United Kingdom, Astex operates as a dedicated pharmaceutical research company with a clinical pipeline that continues to expand alongside its partnered development activities. Strategic partnering remains a core element of its business model, enabling the company to advance multiple assets in parallel with major industry collaborators.

Further information is available at astx.com.